{“title”:”AI-Enabled Clinical Trials Are Poised to Transform How New Medicines Are Tested”,”html”:”Clinical trials have long been the slowest, most expensive and most unpredictable stage of medical research. A promising molecule identified in the laboratory can take a decade or more to traverse the sequence of preclinical studies, phase I safety testing, phase II dose-finding, phase III confirmatory trials and the regulatory submissions that follow. Each step depends on thousands of human decisions: which patients to enrol, which endpoints to measure, how to randomise, how to monitor adverse events, and when to amend a protocol that is no longer performing as intended. Artificial intelligence is now being deployed against nearly all of those decisions at once, and the cumulative effect may be the most significant restructuring of the clinical research enterprise since the randomised controlled trial itself became the gold standard.
The appeal of AI in this setting rests on a simple asymmetry. Clinical trials generate enormous volumes of structured and unstructured data—imaging, laboratory values, genomic profiles, clinician notes, wearable-device streams and patient-reported outcomes—yet historically only a small fraction of that information has been used systematically in trial design and conduct. Machine-learning models, particularly modern deep-learning and foundation-model architectures, excel at extracting signal from exactly these high-dimensional, heterogeneous datasets. When trained on curated clinical data, they can identify which patient subpopulations are most likely to respond to a therapeutic candidate, predict which sites will struggle with recruitment, flag data inconsistencies long before database lock, and estimate the probability that an ongoing trial will meet its primary endpoint. The result is a shift from retrospective, intuition-driven trial management toward a prospectively optimised, continuously adaptive process.
Patient recruitment illustrates the potential most vividly. Failed recruitment and poor participant retention are among the leading reasons that trials miss their timelines or terminate early. Traditional approaches rely on broad eligibility criteria, manual chart review and outreach from a limited number of academic centres, which systematically under-enrols patients from rural areas, lower-income communities and historically marginalised groups. AI-driven approaches invert this model. Natural-language processing systems can scan millions of de-identified electronic health records to locate every patient matching a complex eligibility profile, including patients whose relevant conditions are described only in free-text notes rather than coded diagnoses. Matched patients can then be connected with trial sites through their treating physicians or through decentralised trial infrastructure that brings the study to the participant rather than the reverse. When designed carefully, such tools can also be tuned to improve diversity in enrolment, addressing a long-standing scientific weakness as well as an ethical one: a trial population that does not resemble the eventual treated population limits the generalisability of the results.
Trial design itself is being recomputed. Classical phase II and phase III trials typically use fixed designs conceived months before enrolment begins, and any mid-course revision requires protocol amendments that can delay readouts by many months. AI-assisted design tools draw on large repositories of historical trial outcomes, natural-history data and simulation frameworks to model, before a single patient is enrolled, how a trial will behave under different assumptions about effect size, dropout, endpoint variability and site performance. Bayesian adaptive designs, which allow the randomisation ratio and dose allocation to shift as interim data accumulate, become far more practical when machine-learning models supply reliable predictive components. Digital twins—computational replicas of individual patients built from rich baseline data—offer an emerging complement, allowing a portion of the control information in a trial to be estimated rather than observed, and thereby reducing the number of real participants who must be randomised to achieve a given statistical power. Regulators have begun engaging with these methods, and several external control arms constructed from historical or registry data have already supported regulatory submissions in rare-disease oncology.
Once a trial is running, AI changes the economics of monitoring. Risk-based monitoring, in which scrutiny is concentrated on the sites and data elements most likely to harbour errors, depends on recognising patterns across thousands of simultaneous data streams—precisely the task that anomaly-detection algorithms perform well. Centralised statistical monitoring can flag sites whose data distributions deviate from the norm, whether because of fraud, systematic measurement error or simple process breakdown, without the cost of sending monitors to every site on a fixed schedule. Automated adverse-event signal detection can surface safety trends earlier in the data stream, shortening the interval between an emerging risk and a protocol response. Speech-recognition and summarisation models are increasingly used to draft clinical notes, assist with adjudication of endpoints that require expert review, and reduce the administrative burden that currently consumes a large share of investigator time. Because the marginal cost of applying a trained model to new data is close to zero, these efficiencies can scale across an entire portfolio rather than applying to a single study.
The pharmaceutical industry’s interest follows directly from the arithmetic. Industry analyses have repeatedly estimated that bringing a new drug to market costs on the order of one to two billion dollars, with clinical development accounting for the majority of that expenditure and with most of the cost attributable to failed trials. Even a modest improvement in the probability of technical success, achieved through better target-patient matching or earlier detection of futility, translates into hundreds of millions of dollars in expected savings per programme and, more importantly, into faster access for patients to therapies that work. Every month shaved from a development timeline extends the effective patent-protected market life of a medicine, which strengthens the commercial case, but the public-health case is at least as strong: pipelines that iterate faster can respond more quickly to emerging pathogens, to rare diseases that currently have no treatment at all, and to the individualisation of therapy in fields such as oncology where one-size-fits-all efficacy is the exception rather than the rule.
None of this means the transformation is automatic. Machine-learning models inherit the biases of the data on which they are trained, and clinical datasets under-represent precisely the populations in whom trial evidence is weakest. An algorithm trained mostly on data from large academic hospitals may perform poorly for patients managed in community settings, and a recruitment tool optimised narrowly for speed could worsen enrolment diversity if fairness constraints are not built in explicitly. The opacity of complex models also sits awkwardly with regulatory expectations: a sponsor that uses an AI-derived covariate in a statistical analysis plan, or an AI-curated external control arm, must be able to explain to reviewers how the model was built, validated and monitored. Regulators including the United States Food and Drug Administration and the European Medicines Agency have signalled that they will evaluate such tools under existing frameworks for risk-based software validation, but the guidance landscape is still maturing, and sponsors who treat AI components as unexamined black boxes do so at their own regulatory peril.
Data governance presents a second structural challenge. The models that promise the greatest gains in recruitment and design are those trained on the largest and most diverse clinical datasets, yet health data are fragmented across institutions, jurisdictions and incompatible record systems, and privacy law constrains how they can be pooled. Federated learning, in which models are trained across multiple sites without moving the underlying patient data, offers a technically elegant partial solution, but it introduces its own questions about model ownership, auditability and the equitable distribution of the value created. Standard-setting efforts, from common data models to documented provenance for training sets, will determine whether AI-enabled trials become a broadly shared capability or a competitive advantage concentrated in a handful of organisations with the largest proprietary data estates.
The most realistic near-term picture is therefore not one of autonomous AI running trials, but of a human-machine division of labour in which algorithms perform the enumeration, matching, monitoring and simulation that humans cannot do at scale, while clinicians, statisticians and regulators retain judgment over what counts as evidence. Under that division of labour, the measurable signs of change are already visible: screening times measured in days rather than months at leading sponsors, growing numbers of adaptive and model-informed designs entering regulatory review, and decentralised, data-rich trial formats that were logistically implausible a decade ago. If those trends continue, the defining feature of the next generation of clinical trials will not be any single algorithm but the integration of computation into every stage of the evidentiary pipeline—from the first patient matching query to the final submission—producing trials that are faster, smaller where possible, larger where necessary, and ultimately more representative of the patients the resulting medicines are meant to serve.
“,”excerpt”:”Artificial intelligence is reshaping every stage of clinical development, from patient recruitment and adaptive trial design to safety monitoring and regulatory science.”,”subject”:”The application of artificial intelligence to the design, recruitment, conduct and analysis of clinical trials”,”tags”:[“artificial intelligence”,”clinical trials”,”drug development”,”machine learning”,”patient recruitment”,”adaptive trial design”,”digital twins”,”regulatory science”,”pharmaceutical industry”,”health data”,”deep learning”,”precision medicine”]}”””
Subject of Research: AI-enabled clinical trials
Article Title: AI-enabled clinical trials
Article References: Raynaud, M., Trayanova, N., Mannon, R. B., André, F., Doraiswamy, P. M., & Loupy, A. (2026). AI-enabled clinical trials. Nature Reviews Bioengineering. https://doi.org/10.1038/s44222-026-00487-7
Image Credits: AI Generated
DOI: 10.1038/s44222-026-00487-7
Keywords: AI-enabled, clinical, trials, scientific research, peer-reviewed research, research findings
Cite Scienmag News
APA MLA Chicago
Ophelia Keating. (September 12, 2026). AI-enabled clinical trials. Scienmag. https://scienmag.com/ai-enabled-clinical-trials/
Ophelia Keating. “AI-enabled clinical trials.” Scienmag, 12 September 2026, https://scienmag.com/ai-enabled-clinical-trials/. Accessed 12 September 2026.
Ophelia Keating. “AI-enabled clinical trials.” Scienmag. September 12, 2026. https://scienmag.com/ai-enabled-clinical-trials/
Copy citation Download RIS
Tags: AI for patient recruitment and retentionAI-driven protocol designAI-enabledAI-powered clinical trial optimizationautomation of adverse event detectionclinicaldigital health data integrationgenomic data analysis for personalized medicinemachine learning in drug developmentpeer-reviewed researchpredictive modeling in clinical researchreal-time data monitoring in trialsregulatory implications of AI in healthcareresearch findingsScientific Researchtransformation of traditional clinical research processestrialswearable device data in clinical studies
